Skip to main content

Advertisement

SpringerLink
Log in

High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Our previous study showed that knockdown of high-mobility group A2 (HMGA2) could suppress nasopharyngeal carcinoma (NPC) cell migration, invasion, and epithelial–mesenchymal transition (EMT) process, and HMGA2 is a direct functional target of let-7 to regulate NPC cell migration, invasion, and EMT process. However, little is known about the clinical and prognostic significance of HMGA2 protein in NPC patients. The purpose of this study is to identify the clinical and prognostic roles of HMGA2 in NPC patients. We initially analyzed the microarray data and verified mRNA and protein levels of HMGA2 in NPC tissues. Immunohistochemical staining for HMGA2 protein was performed in 116 NPC patients. The associations between HMGA2 protein expression and clinicopathologic features and its prognostic significance were analyzed. In our results, we found mRNA and protein expressions of HMGA2 were upregulated in NPC tissues and cell lines. In 116 NPC tissue samples, we observed that HMGA2 protein overexpression was associated with clinical stage, lymph node metastasis, and distant metastasis. Moreover, NPC patients with high levels of HMGA2 protein expression had shorter overall survival in comparison to patients with low levels of HMGA2 protein. In multivariate analysis, HMGA2 protein overexpression was an unfavorable prognostic factor for NPC patients. In conclusion, HMGA2 is an important biomarker to predicting NPC patient’s survival time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA 65(2):87–108. doi:10.3322/caac.21262

    PubMed  Google Scholar 

  2. Wei WI, Sham JS (2005) Nasopharyngeal carcinoma. Lancet 365(9476):2041–2054. doi:10.1016/S0140-6736(05)66698-6

    Article  PubMed  Google Scholar 

  3. Zhang L, Zhu YX, Wang Y, Huang CP, Wu Y, Ji QH (2011) Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma: a 10-year experience. Ann Surg Oncol 18(1):233–238. doi:10.1245/s10434-010-1292-9

    Article  PubMed Central  PubMed  Google Scholar 

  4. Hock R, Furusawa T, Ueda T, Bustin M (2007) HMG chromosomal proteins in development and disease. Trends Cell Biol 17(2):72–79. doi:10.1016/j.tcb.2006.12.001

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Pallante P, Sepe R, Puca F, Fusco A (2015) High mobility group a proteins as tumor markers. Front Med 2:15. doi:10.3389/fmed.2015.00015

    Article  Google Scholar 

  6. Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, D’Armiento J, Chada K (2013) HMGA2 is a driver of tumor metastasis. Cancer Res 73(14):4289–4299. doi:10.1158/0008-5472.CAN-12-3848

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, Ai K (2014) H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol 35(9):9163–9169. doi:10.1007/s13277-014-2185-5

    Article  CAS  PubMed  Google Scholar 

  8. Liu Q, Liu T, Zheng S, Gao X, Lu M, Sheyhidin I, Lu X (2014) HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs. Histopathology 65(3):408–417. doi:10.1111/his.12401

    Article  PubMed  Google Scholar 

  9. Ding X, Wang Y, Ma X, Guo H, Yan X, Chi Q, Li J, Hou Y, Wang C (2014) Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition. Cell Prolif 47(2):146–151. doi:10.1111/cpr.12096

    Article  CAS  PubMed  Google Scholar 

  10. Yu H, Lim HH, Tjokro NO, Sathiyanathan P, Natarajan S, Chew TW, Klonisch T, Goodman SD, Surana U, Droge P (2014) Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells. Cell Rep 6(4):684–697. doi:10.1016/j.celrep.2014.01.014

    Article  CAS  PubMed  Google Scholar 

  11. Wei J, Li H, Wang S, Li T, Fan J, Liang X, Li J, Han Q, Zhu L, Fan L, Zhao RC (2014) let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2. Stem Cells Dev 23(13):1452–1463. doi:10.1089/scd.2013.0600

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Wu A, Wu K, Li J, Mo Y, Lin Y, Wang Y, Shen X, Li S, Li L, Yang Z (2015) Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma. J Transl Med 13(1):105. doi:10.1186/s12967-015-0462-8

    Article  PubMed Central  PubMed  Google Scholar 

  13. Wu A, Wu K, Li M, Bao L, Shen X, Li S, Li J, Yang Z (2015) Upregulation of microRNA492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro. Mol Med Rep 12(1):1413–1420. doi:10.3892/mmr.2015.3550

    CAS  PubMed  Google Scholar 

  14. Wang YZ, Wu KP, Wu AB, Yang ZC, Li JM, Mo YL, Xu M, Wu B, Yang ZX (2014) MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer. Tumour Biol 35(10):9815–9821. doi:10.1007/s13277-014-2237-x

    Article  CAS  PubMed  Google Scholar 

  15. Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K, Fang W (2010) Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer 9:78. doi:10.1186/1476-4598-9-78

    Article  PubMed Central  PubMed  Google Scholar 

  16. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V, Fusco A (1995) The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10(7):1307–1314

    CAS  PubMed  Google Scholar 

  17. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J (1996) HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149(3):775–779

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H (1998) The expression pattern of the Hmgic gene during development. Genes Chromosom Cancer 23(4):350–357

    Article  CAS  PubMed  Google Scholar 

  19. Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N (2013) Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 32(45):5272–5282. doi:10.1038/onc.2012.573

    Article  CAS  PubMed  Google Scholar 

  20. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J (1997) Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19(3):153–156

    Article  CAS  PubMed  Google Scholar 

  21. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, Karjalainen A, Knuutila S, Anttila S (2006) Increased expression of high mobility group A proteins in lung cancer. J Pathol 209(2):206–212. doi:10.1002/path.1960

    Article  CAS  PubMed  Google Scholar 

  22. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J (2007) HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46(7):503–511. doi:10.1002/mc.20235

    Article  CAS  PubMed  Google Scholar 

  23. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J (2008) Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosom Cancer 47(1):56–63. doi:10.1002/gcc.20505

    Article  CAS  PubMed  Google Scholar 

  24. Jang MH, Jung KC, Min HS (2015) The diagnostic usefulness of HMGA2, survivin, CEACAM6, and SFN/14-3-3 delta in follicular thyroid carcinoma. J Pathol Transl Med 49(2):112–117. doi:10.4132/jptm.2015.01.31

    Article  PubMed Central  PubMed  Google Scholar 

  25. Raskin L, Fullen DR, Giordano TJ, Thomas DG, Frohm ML, Cha KB, Ahn J, Mukherjee B, Johnson TM, Gruber SB (2013) Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Investig Dermatol 133(11):2585–2592. doi:10.1038/jid.2013.197

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Atomi Y (2003) An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89(11):2104–2109. doi:10.1038/sj.bjc.6601391

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Liang JW, Shi ZZ, Shen TY, Che X, Wang Z, Shi SS, Xu X, Cai Y, Zhao P, Wang CF, Zhou ZX, Wang MR (2014) Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization. PLoS One 9(12):e114616. doi:10.1371/journal.pone.0114616

    Article  PubMed Central  PubMed  Google Scholar 

  28. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K (2004) Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64(6):2024–2029

    Article  CAS  PubMed  Google Scholar 

  29. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M (2008) Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 14(8):2334–2340. doi:10.1158/1078-0432.CCR-07-4667

    Article  CAS  PubMed  Google Scholar 

  30. Yang GL, Zhang LH, Bo JJ, Hou KL, Cai X, Chen YY, Li H, Liu DM, Huang YR (2011) Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer. Eur J Surg Oncol 37(3):265–271. doi:10.1016/j.ejso.2011.01.004

    Article  CAS  PubMed  Google Scholar 

  31. Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y (2010) Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 41(4):493–502. doi:10.1016/j.humpath.2009.08.022

    Article  CAS  PubMed  Google Scholar 

  32. Lee CT, Zhang L, Mounajjed T, Wu TT (2013) High mobility group AT-hook 2 is overexpressed in hepatoblastoma. Hum Pathol 44(5):802–810. doi:10.1016/j.humpath.2012.08.003

    Article  CAS  PubMed  Google Scholar 

  33. Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z, You T (2014) HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett 355(1):130–140. doi:10.1016/j.canlet.2014.09.007

    Article  CAS  PubMed  Google Scholar 

  34. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174(2):175–183. doi:10.1083/jcb.200512110

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A (2008) HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283(48):33437–33446. doi:10.1074/jbc.M802016200

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M, Kudo E, Sano T (2009) Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 22(3):431–441. doi:10.1038/modpathol.2008.202

    Article  CAS  PubMed  Google Scholar 

  37. Lee J, Ha S, Jung CK, Lee HH (2015) High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition. Int J Oncol. doi:10.3892/ijo.2015.2947

    PubMed Central  Google Scholar 

  38. Liu B, Pang B, Hou X, Fan H, Liang N, Zheng S, Feng B, Liu W, Guo H, Xu S, Pang Q (2014) Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum Pathol 45(8):1752–1758. doi:10.1016/j.humpath.2014.02.028

    Article  CAS  PubMed  Google Scholar 

  39. Wu L, Wang Z, Lu R, Jiang W (2012) Expression of high mobility group A2 is associated with poor survival in hepatocellular carcinoma. Pathol Oncol Res 18(4):983–987. doi:10.1007/s12253-012-9514-z

    Article  PubMed  Google Scholar 

  40. Xia YY, Yin L, Tian H, Guo WJ, Jiang N, Jiang XS, Wu J, Chen M, Wu JZ, He X (2015) HMGA2 is associated with epithelial-mesenchymal transition and can predict poor prognosis in nasopharyngeal carcinoma. OncoTargets Ther 8:169–176. doi:10.2147/OTT.S74397

    Article  Google Scholar 

  41. Kong D, Su G, Zha L, Zhang H, Xiang J, Xu W, Tang Y, Wang Z (2014) Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer. Med Oncol 31(8):130. doi:10.1007/s12032-014-0130-5

    Article  PubMed  Google Scholar 

  42. Califano D, Pignata S, Losito NS, Ottaiano A, Greggi S, De Simone V, Cecere S, Aiello C, Esposito F, Fusco A, Chiappetta G (2014) High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol 229(1):53–59. doi:10.1002/jcp.24416

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the funding from the National Natural Science Foundation of China (No. 81201672), the Doctoral Program of Affiliated Hospital of Guangdong Medical College (No. BK201208), and the Science and Technology Planning Project of Guangdong Province (No. 2013B021800078).

Author information

Authors and Affiliations

  1. Cancer Center, Heyuan People’s Hospital, No. 733 Wenxiang Road, Heyuan, 517000, Guangdong, People’s Republic of China

    Zhuoxing Liu & Kunpeng Wu

  2. Cancer Center, Affiliated Hospital of Guangdong Medical College, No. 57 People’s Avenue South, Zhanjiang, 524002, Guangdong, People’s Republic of China

    Zhixiong Yang & Aibing Wu

Authors
  1. Zhuoxing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kunpeng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhixiong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aibing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kunpeng Wu, Zhixiong Yang or Aibing Wu.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Z., Wu, K., Yang, Z. et al. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients. Mol Cell Biochem 409, 155–162 (2015). https://doi.org/10.1007/s11010-015-2521-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-015-2521-0

Keywords

Search

Navigation